Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat

Neuropsychopharmacology

Volumn 27, Issue 5, 2002, Pages 691-698

  Linnér, Love ^a   Wiker, Charlotte ^a   Wadenberg, Marie Louise ^a   Schalling, Martin ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic; Behavior; Dopamine; Microdialysis; Noradrenaline

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; RACLOPRIDE TARTRATE; REBOXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; DOPAMINE; DRUG SYNERGISM; MALE; MORPHOLINES; NOREPINEPHRINE; PREFRONTAL CORTEX; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 0036850564     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00350-0     Document Type: Article

References (46)

1. Ahlenius S., Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs. a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission Pharmacol Biochem Behav. 24:1986;1409-1415.
2. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol. 352:1995;374-385.
3. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats. inhibition by neuroleptics and correlation to dopamine receptor blockade Acta Pharmacol Toxicol (Copenh). 51:1982;321-329.
4. Ashby C.R. Jr., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine. a review Synapse. 24:1996;349-394.
5. Berk M., Ichim C., Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia. a double-blind randomized placebo-controlled study Int Clin Psychopharmacol. 16:2001;87-92.
6. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex. evidence that dopamine is taken up in vivo by noradrenergic terminals J Neurochem. 55:1990;1067-1070.
7. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
8. Carpenter WT Jr (1996): The treatment of negative symptoms: Pharmacological and methodological issues. Br J Psychiatry Suppl:17-22
9. Castner S.A., Williams G.V., Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 287:2000;2020-2022.
10. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther. 241:1987;642-649.
11. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 45:1988;71-76.
12. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 49:1992;538-544.
13. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology. 22:2000;642-649.
14. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol. 233:1993;79-84.
15. Gresch P.J., Sved A.F., Zigmond M.J., Finlay J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem. 65:1995;111-116.
16. Grinshpoon A., Valevski A., Moskowitz M., Weizman A. Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 15:2000;388-390.
17. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone. regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain Psychopharmacology (Berl). 124:1996;74-86.
18. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286:1999;105-107. a.
19. Hertel P., Nomikos G.G., Svensson T.H. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J Pharmacol. 371:1999;153-158. b.
20. Imperato A., Angelucci L. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull. 25:1989;383-389.
21. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
22. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 45:1988;789-796.
23. Kohler C., Hall H., Ogren S.O., Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 34:1985;2251-2259.
24. Linner L., Endersz H., Ohman D., Bengtsson F., Schalling M., Svensson T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther. 297:2001;540-546.
25. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry. 168:1996;571-579.
26. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
27. Mizuki Y., Kajimura N., Imai T., Suetsugi M., Kai S., Kaneyuki H., Yamada M. Effects of mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol. 5:1990;83-95.
28. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat. an in vivo microdialysis study J Neurochem. 54:1990;1755-1760.
29. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl). 115:1994;147-156.
30. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 4th ed:1998;Academic Press, London.
31. Petit M., Raniwalla J., Tweed J., Leutenegger E., Dollfus S., Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia. a parallel-group double-blind trial Psychopharmacol Bull. 32:1996;81-87.
32. Preuss T.M. Do rats have prefrontal cortex? The Rose-Woolsey-Akert program reconsidered. J Cogn Neurosci. 7:1995;1-24.
33. Rowley H.L., Needham P.L., Kilpatrick I.C., Heal D.J. A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. Naunyn Schmiedebergs Arch Pharmacol. 361:2000;187-192.
34. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol. 128:1999;1332-1338.
35. Safferman A., Lieberman J.A., Kane J.M., Szymanski S., Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 17:1991;247-261.
36. Siegel S., Castellan N.J. Jr. Nonparametric statistics for the behavioral sciences. 1988;McGraw-Hill, New York.
37. Svensson T.H., Nomikos G.G., Andersson J.L. Modulation of dopaminergic neurotransmission by 5-HT2 antagonism. Vanhouette P.M., Saxena P.R., Paoletti R., Brunello N., Jackson A.S. Serotonin. from Cell Biology to Pharmacology and Therapeutics:1993;263-270 Kluwer Academic Publishers, Dordrecht.
38. Svensson T.H., Mathe J.M., Andersson J.L., Nomikos G.G., Hildebrand B.E., Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia. role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism J Clin Psychopharmacol. 15(Suppl 1):1995;11S-18S.
39. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat. enhancement of antipsychotic-like effects without catalepsy J Neural Transm Gen Sect. 83:1991;43-53.
40. Wadenberg M.L., Salmi P., Jimenez P., Svensson T., Ahlenius S. Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol. 6:1996;305-310.
41. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated. is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev. 23:1999;851-862.
42. Wadenberg M.L., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl). 150:2000;422-429.
43. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
44. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol. 412:2001;127-138.
45. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine. a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol Psychiatry. 47:2000;818-829.
46. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem. 71:1998;274-280.